Propanc Surges 205% as Rival's FDA Approval Validates Its Pancreatic Cancer Data
PPCB has more than doubled off its 52-week low of $0.95 on elevated volume (16× avg).
Summary
Propanc Biopharma shares jumped 205.60% to $3.26 on Thursday after the FDA approved Revolution Medicines' daraxonrasib for metastatic pancreatic cancer, which the market reads as validation for Propanc's own PRP candidate. The company's preclinical data, first reported August 6, showed >90% tumor growth inhibition and >2.5-fold survival extension in aggressive pancreatic cancer models. The approval of a competitor's drug in the same indication is being interpreted as a positive signal for the entire class of novel pancreatic cancer therapies. Propanc plans to submit a clinical trial application in the coming months for a Phase 1b study in 40-45 patients with advanced solid tumors. The stock's massive move on high volume suggests traders are repositioning ahead of that milestone.
At the time of this announcement, PPCB was trading at $2.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7M. The 52-week trading range was $0.95 to $85.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.